Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Merck
Colorcon
Moodys
Express Scripts

Last Updated: November 11, 2019

DrugPatentWatch Database Preview

Litigation Details for CELGENE CORPORATION v. NATCO PHARMA LIMITED (D.N.J. 2010)

See Plans and Pricing

« Back to Dashboard

CELGENE CORPORATION v. NATCO PHARMA LIMITED (D.N.J. 2010)

Docket   Start Trial Date Filed 2010-10-08
Court District Court, D. New Jersey Date Terminated 2016-01-05
Cause 35:271 Patent Infringement Assigned To Susan Davis Wigenton
Jury Demand None Referred To Leda D. Wettre
Parties ANDA, INC; ARROW INTERNATIONAL LIMITED; CELGENE CORPORATION; NATCO PHARMA LIMITED; WATSON LABORATORIES, INC.; WATSON PHARMA, INC.; WATSON PHARMACEUTICALS, INC.
Patents 5,635,517; 6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 7,119,106; 7,189,740; 7,465,800; 7,968,569; 8,204,763; 8,288,415; 8,315,886
Attorneys BRIAN JOHN FORSATZ; CATHERINE THISBE MATTES; CHARLES MICHAEL LIZZA; FRANK CHARLES CALVOSA; JAMES S. RICHTER; JEFFREY P. CATENACCI; MELISSA STEEDLE BOGAD; WILLIAM C. BATON
Firms Quinn Emanuel Uquhart & Sullival LLP; Quinn Emanuel Urquhart & Sullivan LLC; Quinn Emanuel Urquhart & Sullivan, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. NATCO PHARMA LIMITED
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in CELGENE CORPORATION v. NATCO PHARMA LIMITED
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for CELGENE CORPORATION v. NATCO PHARMA LIMITED (D.N.J. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-10-08 1 Complaint United States Patent Nos. 5,635,517 (the “’517 patent”), 6,045,501 (the “’501 patent”), 6,281,230 (… (the “’230 patent”), 6,315,720 (the “’720 patent”), 6,555,554 (the “’554 patent”), 6,561,976 (the “…PageID: 2 “’784 patent”), 7,119,106 (the “’106 patent”), and 7,465,800 (the “’800 patent”) owned by Celgene… 1. This is an action for patent infringement under the patent laws of the United States, 35 … “’976 patent”), 6,561,977 (the “’977 patent”), 6,755,784 (the Case 2:10-cv-05197-SDW-LDW Document 1 Filed External link to document
2012-11-13 151 Motion to Dismiss Counterclaims Pertaining to United States Patent No. 8,204,763 (Counts XIII through XV) by CELGENE CORPORATION…2010 5 January 2016 2:10-cv-05197 830 Patent None District Court, D. New Jersey External link to document
2012-11-13 152 Brief in Support of Motion Counterclaims Pertaining to United States Patent No. 8,204,763 (Counts XIII through XV) (Confidential Version…2010 5 January 2016 2:10-cv-05197 830 Patent None District Court, D. New Jersey External link to document
2012-11-30 155 Letter Rule 7.1 Counterclaims Pertaining to United States Patent No. 8,204,763 (Counts XIII through XV) . (CATENACCI, JEFFREY…2010 5 January 2016 2:10-cv-05197 830 Patent None District Court, D. New Jersey External link to document
2012-12-26 158 Letter Counterclaims Pertaining to United States Patent No. 8,204,763 (Counts XIII through XV), Set/Reset Motion…2010 5 January 2016 2:10-cv-05197 830 Patent None District Court, D. New Jersey External link to document
2012-12-28 159 Brief in Opposition to Motion Counterclaims Pertaining to United States Patent No. 8,204,763 (Counts XIII through XV) (CATENACCI, JEFFREY…2010 5 January 2016 2:10-cv-05197 830 Patent None District Court, D. New Jersey External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Mallinckrodt
Express Scripts
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.